Pipeline

We have a unique approach to our pipeline, reflective of our unique turnaround process.

After promising drugs have demonstrated therapeutic effect, but stall in their development, we look to acquire and turn them around using SAFEPATH and our strategic approach to clinical development. Our bespoke identify and solve stages are key to springboarding new treatments back to patients.

The turnaround symbol represents at what stage of development we acquired the asset originally, and the blue line represents where Ignota Labs is developing it today.

  • Indication

    Autoimmune disease (ITP and wAIHA)

    Target
    SYK
    Turnaround Plan

    Previous Phase 2 trials for this asset (lanraplenib) did not succeed, largely due to challenges in clinical positioning and trial execution rather than limitations of the mechanism itself. SYK is a pivotal kinase in immune cell signalling and a validated driver of disease in both ITP and wAIHA. In ITP, our inhibitor is designed to achieve best-in-class efficacy while avoiding the toxicity seen with the currently approved therapy. Positioning lanraplenib in wAIHA is a first-in-class opportunity.

    Identify issue
    Solve
    Candidate selection
    IND
    Phase 1
    Phase 2
    Phase 3
  • Indication

    Kidney and cardio-metabolic diseases

    Target
    PDE9
    Turnaround Plan

    The initial chemical series encountered genotoxicity during candidate selection, preventing advancement. PDE9 remains a compelling mechanism, capable of influencing multiple pathways relevant to complex diseases. Our approach is to overcome the earlier toxicity limitations through new chemistry and improved profiling. By doing so, we aim to unlock the potential of PDE9 inhibition for patients with overlapping cardio-metabolic and renal morbidities, where safe and effective treatment options are still lacking.

    Identify issue
    Solve
    Candidate selection
    IND
    Phase 1
    Phase 2
    Phase 3
  • Indication

    Acute Myeloid Leukemia (AML)

    Target
    CDK9
    Turnaround Plan

    This programme was acquired at Phase 2 following the emergence of neurotoxicity. CDK9 remains a highly promising target, with best-in-class credentials driven by excellent kinase selectivity and oral bioavailability. Our strategy is to reduce brain penetration and optimise pharmacokinetics, unlocking the full therapeutic potential of this target class.

    Identify issue
    Solve
    Candidate selection
    IND
    Phase 1
    Phase 2
    Phase 3
  • Indication

    Blood cancers and solid tumours

    Target
    Undisclosed
    Turnaround Plan

    To be announced

    Identify issue
    Solve
    Candidate selection
    IND
    Phase 1
    Phase 2
    Phase 3
  • Additional programmes identified

    Further assets identified and assessed, ready to acquire

    Identify issue
    Solve
    Candidate selection
    IND
    Phase 1
    Phase 2
    Phase 3